Literature DB >> 23656447

Medicines counterfeiting is a complex problem: a review of key challenges across the supply chain.

Michael Tremblay1.   

Abstract

The paper begins by asking why there is a market for counterfeit medicines, which in effect creates the problem of counterfeiting itself. Contributing factors include supply chain complexity and the lack of whole-systems thinking. These two underpin the author's view that counterfeiting is a complex (i.e. wicked) problem, and that corporate, public policy and regulatory actions need to be mindful of how their actions may be causal. The paper offers a problem-based review of key components of this complexity, viz., the knowledge end-users/consumers have of medicines; whether restrictive information policies may hamper information provision to patients; the internet's direct access to consumers; internet-enabled distribution of unsafe and counterfeit medicines; whether the internet is a parallel and competitive supply chain to legitimate routes; organised crime as an emerging medicines manufacturer and supplier and whether substandard medicines is really the bigger problem. Solutions respect the perceived complexity of the supply chain challenges. The paper identifies the need to avoid technologically-driven solutions, calling for 'technological agnosticism'. Both regulation and public policy need to reflect the dynamic nature of the problem and avoid creating perverse incentives; it may be, for instance, that medicines pricing and reimbursement policies, which affect consumer/patient access may act as market signals to counterfeiters, since this creates a cash market in cheaper drugs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23656447     DOI: 10.2174/1574886311308010007

Source DB:  PubMed          Journal:  Curr Drug Saf        ISSN: 1574-8863


  7 in total

1.  Responding to the pandemic of falsified medicines.

Authors:  Gaurvika M L Nayyar; Amir Attaran; John P Clark; M Julia Culzoni; Facundo M Fernandez; James E Herrington; Megan Kendall; Paul N Newton; Joel G Breman
Journal:  Am J Trop Med Hyg       Date:  2015-04-20       Impact factor: 2.345

2.  Counterfeit drug penetration into global legitimate medicine supply chains: a global assessment.

Authors:  Tim K Mackey; Bryan A Liang; Peter York; Thomas Kubic
Journal:  Am J Trop Med Hyg       Date:  2015-04-20       Impact factor: 2.345

3.  The Quality of Medicines Used in Children and Supplied by Private Pharmaceutical Wholesalers in Kinshasa, Democratic Republic of Congo: A Prospective Survey.

Authors:  Benedetta Schiavetti; Evelien Wynendaele; Bart De Spiegeleer; Geremie J Mbinze; Nicodème Kalenda; Roland Marini; Vera Melotte; Epco Hasker; Bruno Meessen; Raffaella Ravinetto; Josiane Van der Elst; Daniel Mutolo Ngeleka
Journal:  Am J Trop Med Hyg       Date:  2018-01-04       Impact factor: 2.345

4.  Managing uncertainty in medicine quality in Ghana: The cognitive and affective basis of trust in a high-risk, low-regulation context.

Authors:  Heather Hamill; Kate Hampshire; Simon Mariwah; Daniel Amoako-Sakyi; Abigail Kyei; Michele Castelli
Journal:  Soc Sci Med       Date:  2019-06-12       Impact factor: 4.634

5.  "It is very difficult in this business if you want to have a good conscience": pharmaceutical governance and on-the-ground ethical labour in Ghana.

Authors:  Kate Hampshire; Simon Mariwah; Daniel Amoako-Sakyi; Heather Hamill
Journal:  Glob Bioeth       Date:  2022-07-26

6.  Counterfeit medicines in Peru: a retrospective review (1997-2014).

Authors:  Edwin Medina; Elvira Bel; Josep María Suñé
Journal:  BMJ Open       Date:  2016-04-04       Impact factor: 2.692

Review 7.  Regulatory framework in Pakistan: situation analysis of medicine quality and future recommendations.

Authors:  Huma Rasheed; Ludwig Hoellein; Khalid Saeed Bukhari; Ulrike Holzgrabe
Journal:  J Pharm Policy Pract       Date:  2019-09-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.